Literature DB >> 6092271

Lipopolysaccharide-induced suppressor cells for delayed-type hypersensitivity to herpes simplex virus: nature of suppressor cell and effect on pathogenesis of herpes simplex.

D M Altmann, W A Blyth.   

Abstract

Treatment of mice with LPS at the time of priming with herpes simplex virus type 1 (HSV1) causes the preferential activation of virus-specific T suppressor (Ts) cells. These Ts cells can transfer suppression to the efferent limb of a DTH response. Priming under these conditions is associated with enhanced cell-recruitment to the inoculation site, but had no effect on virus clearance. The induction of suppression was abrogated by pretreatment of mice with cyclophosphamide or indomethacin. LPS had no effect on the antibody response to HSV1 during acute infection, although treated mice showed a raised antibody titre one month after inoculation. Susceptible mice inoculated with HSV1 and given LPS showed protection, both from lethal herpes encephalitis and from demyelination within the CNS as reflected by ear paralysis. These results imply that, during some stages of acute infection, T cell effector mechanisms may themselves mediate tissue damage. At such times, Ts cells may perform a beneficial role leading to a reduction in pathology.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6092271      PMCID: PMC1454909     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  20 in total

1.  Analysis of immunosuppression generated by the graft-versus-host reaction. I. A suppressor T-cell component studied in vivo.

Authors:  F L Shand
Journal:  Immunology       Date:  1975-12       Impact factor: 7.397

2.  Lipopolysaccharide-induced suppression of the primary immune response to a thymus-dependent antigen.

Authors:  U Persson
Journal:  J Immunol       Date:  1977-03       Impact factor: 5.422

3.  Morphology of central nervous system disease in immunosuppressed mice after peripheral herpes simplex virus inoculation. Trigeminal root entry zone.

Authors:  J J Townsend; J R Baringer
Journal:  Lab Invest       Date:  1979-02       Impact factor: 5.662

4.  A rapid method for the isolation of functional thymus-derived murine lymphocytes.

Authors:  M H Julius; E Simpson; L A Herzenberg
Journal:  Eur J Immunol       Date:  1973-10       Impact factor: 5.532

5.  Effect of antithymocyte serum on herpesvirus hominis (type 1) infection in adult mice.

Authors:  A J Nahmias; M S Hirsch; J H Kramer; F A Murphy
Journal:  Proc Soc Exp Biol Med       Date:  1969-11

6.  Resistance of nude mice to herpes simplex virus and correlation with in vitro production of interferon.

Authors:  R Zawatzky; J Hilfenhaus; H Krichner
Journal:  Cell Immunol       Date:  1979-10       Impact factor: 4.868

7.  The induction of suppressor T cells by lipopolysaccharide in human peripheral blood lymphocyte cultures in the presence of fetal calf serum.

Authors:  R A Miller; S Gartner; H S Kaplan
Journal:  Cell Immunol       Date:  1980-09-15       Impact factor: 4.868

8.  Regulation of delayed-type hypersensitivity IV. Antigen-specific suppressor cells for delayed-type hypersensitivity induced by lipopolysaccharide and sheep erythrocytes in mice.

Authors:  H K Gill; F Y Liew
Journal:  Eur J Immunol       Date:  1979-02       Impact factor: 5.532

9.  Activation of T and B lymphocytes in vitro. I. Regulatory influence of bacterial lipopolysaccharide (LPS) on specific T-cell helper function.

Authors:  D Armerding; D H Katz
Journal:  J Exp Med       Date:  1974-01-01       Impact factor: 14.307

10.  Differential effects of polyadenylic: polyuridylic acid and lipopolysaccharide on the generation of cytotoxic T lymphocytes.

Authors:  P R Narayanan; G Sundharadas
Journal:  J Exp Med       Date:  1978-05-01       Impact factor: 14.307

View more
  1 in total

1.  Herpes simplex virus-induced stromal keratitis: role of T-lymphocyte subsets in immunopathology.

Authors:  C K Newell; S Martin; D Sendele; C M Mercadal; B T Rouse
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.